BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone919-582-9050
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$61.99 million
Profitability
Miscellaneous
Employees116
OptionableOptionable
BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions
What is BioDelivery Sciences International's stock symbol?
BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."
How were BioDelivery Sciences International's earnings last quarter?
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) released its quarterly earnings results on Thursday, November, 8th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.04. The specialty pharmaceutical company earned $14.16 million during the quarter, compared to analyst estimates of $14.21 million. BioDelivery Sciences International had a negative return on equity of 141.35% and a negative net margin of 85.93%. View BioDelivery Sciences International's Earnings History.
When is BioDelivery Sciences International's next earnings date?
What price target have analysts set for BDSI?
5 analysts have issued 12 month target prices for BioDelivery Sciences International's stock. Their predictions range from $4.00 to $5.00. On average, they expect BioDelivery Sciences International's stock price to reach $4.80 in the next twelve months. This suggests a possible upside of 11.4% from the stock's current price. View Analyst Price Targets for BioDelivery Sciences International.
What is the consensus analysts' recommendation for BioDelivery Sciences International?
What are Wall Street analysts saying about BioDelivery Sciences International stock?
Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
- 1. According to Zacks Investment Research, "BioDelivery secured improved positioning in several managed care contracts providing preferred access to Belbuca. The company’s efforts has brought 100 million patients under preferred coverage so far this year, having started the year with 7 million. This has already started to boost the drug’s sales and profitability in 2018. Belbuca’s prescriptions has grown sequentially every quarter in 2018. Increase in sales force has supported the growth. BioDelivery’s shares have outperformed the industry in the past six months. However, given the lackluster performance of Bunavail, BioDelivery decided to reduce spending on the drug. Moreover, the company’s portfolio as well as its pipeline candidates may also face severe competition as it targets a highly genericized and crowded market." (1/18/2019)
- 2. Cantor Fitzgerald analysts commented, ". After a day of meetings with BDSI CEO Herm Cukier earlier this week, we are reiterating our Overweight rating and 12-month price target of $5. We view BDSI as a Belbuca execution story, and, based on Symphony script data so far in 2018, the company is exceeding its execution goals as well as our expectations. The sentiment at the meetings was positive with a common theme of delving into whether the company has the foundation to continue to execute in 2019 as it has in 2018. Following the meetings, we have increased conviction that solid execution in 2019 and beyond is likely to continue, which should drive upward earnings revisions and further upside in BDSI stock. Detailed takeaways are below." (12/13/2018)
- 3. HC Wainwright analysts commented, "Our $5, 12-month price target is based on a DCF reflecting strong Belbuca growth to over $150M by 2022, cash- flow breakeven by end-2019, and overall profitability in 2020. Our DCF reflects a 10.5% WACC discount and negative -15% terminal value beyond 2027, and includes 93M shares (post-financing, plus other currently anti-dilutive shares)." (11/2/2018)
Has BioDelivery Sciences International been receiving favorable news coverage?
Headlines about BDSI stock have been trending somewhat positive on Friday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioDelivery Sciences International earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of BioDelivery Sciences International's key competitors?
Some companies that are related to BioDelivery Sciences International include Clovis Oncology (CLVS), Uniqure (QURE), Esperion Therapeutics (ESPR), Kiniksa Pharmaceuticals (KNSA), Spectrum Pharmaceuticals (SPPI), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), Tricida (TCDA), Retrophin (RTRX), Homology Medicines (FIXX), Apellis Pharmaceuticals (APLS), Lexicon Pharmaceuticals (LXRX) and Inflarx (IFRX).
Who are BioDelivery Sciences International's key executives?
BioDelivery Sciences International's management team includes the folowing people:
- Mr. Ernest Robert De Paolantonio CPA, MBA, CFO & Treasurer (Age 65)
- Mr. Herm Cukier, CEO & Director (Age 52)
- Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 54)
- Mr. Joseph M. Lockhart, Sr. VP of Operations
- Ms. Mary Coleman, VP of Investor & PR
How do I buy shares of BioDelivery Sciences International?
Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioDelivery Sciences International's stock price today?
One share of BDSI stock can currently be purchased for approximately $4.31.
How big of a company is BioDelivery Sciences International?
BioDelivery Sciences International has a market capitalization of $299.80 million and generates $61.99 million in revenue each year. The specialty pharmaceutical company earns $5.28 million in net income (profit) each year or ($0.39) on an earnings per share basis. BioDelivery Sciences International employs 116 workers across the globe.
What is BioDelivery Sciences International's official website?
How can I contact BioDelivery Sciences International?
BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]
MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
